The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway

The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway

Background/Aims: This study aimed to determine whether or not the sodium-glucose co-transporter 2 inhibitor, empagliflozin (EMPA), can protect against diabetic cardiomyopathy (DCM) and to elucidate the related mechanism. Methods: Rats were divided into the following four groups: a non-diabetic group...

Full description

Bibliographic Details
Main Authors: Yang Zhou, Wei Wu
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2017-05-01
Series:Cellular Physiology and Biochemistry
Subjects:
Diabetic cardiomyopathy
Empagliflozin
Endoplasmic reticulum stress
Online Access:http://www.karger.com/Article/FullText/475942

Internet

http://www.karger.com/Article/FullText/475942

Similar Items